ACUT fundamentals

Key facts

—

—

—

—

—

—

—

—

About

AccuStem Sciences, Inc. is a clinical stage diagnostics company, which engages in medical practice activities. It also focuses on commercialization of a proprietary genomic test, StemPrintER, for patients with early-stage breast cancer. The company was founded by Gabriele Marco Antonio Cerrone on June 5, 2020 and is headquartered in New York, NY.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

ACUT has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company